Helena W. Rodbard, MD, FACP, MACE
Michael A. Dempsey, MD, FACP
Board-Certified Endocrinologists
We are located at
3200 Tower Oaks Boulevard | Suite 250
Rockville, MD 20852
Current Clinical Trials
Our current clinical trials explore new, as well as existing, medical therapies which will improve glucose control in people with Diabetes.
All study-related care, diabetes education and medications are provided at no charge. Medical insurance is not neccessary for study participation.
The average duration of a clinical trial is 6-12 months.
The benefits of participation in a clinical trial include intensive management of your Diabetes; access to the most recent advances in investigational therapy; close, personalized follow-up by a board-certified endocrinologist; and the opportunity to help in the development of improved therapies for the management of Diabetes.
Type 1 Diabetes
We are have participated in many interesting studies designed to evaluate new treatment options for people with Type 1 Diabetes treated with injections as well as those treated with insulin pumps.
Oral and injectable investigational medications are being studied at our center.
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of tirzepatide once weekly compared to placebo in adults with type 1 who are obese or overweight will begin recruitment in May 2025
If you're interested in discussing future trial opportunities, please call our office at 301-770-7373 for further information. Ask for someone from the Study Staff.
Type 2 Diabetes
There are currently multiple ongoing clinical trials at our research center actively enrolling subjects with Type 2 Diabetes.
In May 2025 we'll begin enrolling a study investigating the safety and efficacy of a once daily oral product in people with obesity (or overweight with a weight-related comorbidity)
Please call us to review trials at 301-770-7373.
Overweight or Obese?
Recruitment for a study investigating the efficacy and safety of a once daily oral product in people with obesity (or overweight with weight-related comorbidities) will begin recruitment in May 2025.
People with or without type 2 diabetes are eligible.
Please call our office at 301-770-7373 to discuss with Dr Dempsey, our Research Director.